Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407
Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. A significant...
Saved in:
Published in | Clinical and vaccine immunology Vol. 23; no. 1; pp. 55 - 64 |
---|---|
Main Authors | , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
American Society for Microbiology
01.01.2016
|
Subjects | |
Online Access | Get full text |
ISSN | 1556-6811 1556-679X |
DOI | 10.1128/CVI.00617-15 |
Cover
Abstract | Enterotoxigenic
Escherichia coli
(ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. A significant challenge to successful vaccine development is our poor understanding of the immune responses that correlate best with protection against ETEC illness. In this study, ETEC-specific mucosal immune responses were characterized and compared in subjects challenged with ETEC strain H10407 and in subjects rechallenged with the homologous organism. IgA responses to lipopolysaccharide (LPS), heat-labile toxin B subunit (LTB), and colonization factor antigen I (CFA/I) in antibody in lymphocyte supernatant (ALS), feces, lavage fluid, and saliva samples were evaluated. In all assay comparisons, ALS was the most sensitive indicator of a local immune response, but serum IgA was also a useful indirect marker of immune response to oral antigens. Volunteers challenged and then rechallenged with strain H10407 were protected from illness following rechallenge. Comparing mucosal antibody responses after primary and homologous rechallenge, protection against disease was reflected in reduced antibody responses to key ETEC antigens and in reduced fecal shedding of the H10407 challenge strain. Subjects challenged with strain H10407 mounted stronger antibody responses to LPS and LTB than subjects in the rechallenge group, while responses to CFA/I in the rechallenge group were higher than in the challenge group. We anticipate that this study will help provide an immunological benchmark for the evaluation of ETEC vaccines and immunization regimens in the future. |
---|---|
AbstractList | Enterotoxigenic
Escherichia coli
(ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. A significant challenge to successful vaccine development is our poor understanding of the immune responses that correlate best with protection against ETEC illness. In this study, ETEC-specific mucosal immune responses were characterized and compared in subjects challenged with ETEC strain H10407 and in subjects rechallenged with the homologous organism. IgA responses to lipopolysaccharide (LPS), heat-labile toxin B subunit (LTB), and colonization factor antigen I (CFA/I) in antibody in lymphocyte supernatant (ALS), feces, lavage fluid, and saliva samples were evaluated. In all assay comparisons, ALS was the most sensitive indicator of a local immune response, but serum IgA was also a useful indirect marker of immune response to oral antigens. Volunteers challenged and then rechallenged with strain H10407 were protected from illness following rechallenge. Comparing mucosal antibody responses after primary and homologous rechallenge, protection against disease was reflected in reduced antibody responses to key ETEC antigens and in reduced fecal shedding of the H10407 challenge strain. Subjects challenged with strain H10407 mounted stronger antibody responses to LPS and LTB than subjects in the rechallenge group, while responses to CFA/I in the rechallenge group were higher than in the challenge group. We anticipate that this study will help provide an immunological benchmark for the evaluation of ETEC vaccines and immunization regimens in the future. Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers. Although there are several approaches to develop an effective vaccine for ETEC, no licensed vaccines are currently available. A significant challenge to successful vaccine development is our poor understanding of the immune responses that correlate best with protection against ETEC illness. In this study, ETEC-specific mucosal immune responses were characterized and compared in subjects challenged with ETEC strain H10407 and in subjects rechallenged with the homologous organism. IgA responses to lipopolysaccharide (LPS), heat-labile toxin B subunit (LTB), and colonization factor antigen I (CFA/I) in antibody in lymphocyte supernatant (ALS), feces, lavage fluid, and saliva samples were evaluated. In all assay comparisons, ALS was the most sensitive indicator of a local immune response, but serum IgA was also a useful indirect marker of immune response to oral antigens. Volunteers challenged and then rechallenged with strain H10407 were protected from illness following rechallenge. Comparing mucosal antibody responses after primary and homologous rechallenge, protection against disease was reflected in reduced antibody responses to key ETEC antigens and in reduced fecal shedding of the H10407 challenge strain. Subjects challenged with strain H10407 mounted stronger antibody responses to LPS and LTB than subjects in the rechallenge group, while responses to CFA/I in the rechallenge group were higher than in the challenge group. We anticipate that this study will help provide an immunological benchmark for the evaluation of ETEC vaccines and immunization regimens in the future. |
Author | Sack, David A. DeNearing, Barbara Bourgeois, A. Louis Walker, Richard Chakraborty, Subhra Cage, Alicia Ram, Malathi Bauers, Nicole Feller, Andrea Harro, Clayton |
Author_xml | – sequence: 1 givenname: Subhra surname: Chakraborty fullname: Chakraborty, Subhra organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 2 givenname: Clayton surname: Harro fullname: Harro, Clayton organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 3 givenname: Barbara surname: DeNearing fullname: DeNearing, Barbara organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 4 givenname: Malathi surname: Ram fullname: Ram, Malathi organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 5 givenname: Andrea surname: Feller fullname: Feller, Andrea organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 6 givenname: Alicia surname: Cage fullname: Cage, Alicia organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA – sequence: 7 givenname: Nicole surname: Bauers fullname: Bauers, Nicole organization: PATH, Washington, DC, USA – sequence: 8 givenname: A. Louis surname: Bourgeois fullname: Bourgeois, A. Louis organization: PATH, Washington, DC, USA – sequence: 9 givenname: Richard surname: Walker fullname: Walker, Richard organization: PATH, Washington, DC, USA – sequence: 10 givenname: David A. surname: Sack fullname: Sack, David A. organization: Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/26581889$$D View this record in MEDLINE/PubMed |
BookMark | eNqNksuO0zAYhS00iLnAjjXykgUdfIvjsEAaVYVWmhGIy4id5Th2Y-TYndjh9p68D247UwFiwSqO_P3nHNvnFByFGAwAjzE6x5iI5_Pr1TlCHNczXN0DJ7iq-IzXzaeju7XA-BicpvQZIUa5qB-AY8IrgYVoTsDPea9GpbMZ3Q-VXQwwWng16ZiUh6thmIKB70zaxJBMgjnCRShszPGbW5vgNFwk3Zdh3TsFdfQOXiutXZm6CHmLJOgCVHA5DSrAYua9CWsDr2Jn_IuDNHw7Rut8sVC26JdfN6jxO1wFa_QulgodXMYh-riOUyqD-qD11eUevs-jKk5LjBiqH4L7VvlkHt1-z8DHV4sP8-Xs8s3r1fzicqYZrvNMmc5SoRvNWUtbxBvVYsGttZTgjiKiRasoJQRbViDLmopyjlHDaGOYIJaegZd73c3UDqbTJpQUXm726WVUTv65E1wv1_GLZDUuOlUReHorMMabyaQsB5e08V4FU44pcc0J5U3N_wtFgjMsSEGf_B7rkOfu2QvwbA_oMaY0GntAMJLbVsnSKrlrlcRba_IXrl3etWV76f7fQ78ALZ3UBg |
CitedBy_id | crossref_primary_10_1128_CVI_00276_17 crossref_primary_10_69833_RSVM_2024_1_44_02 crossref_primary_10_1016_j_lfs_2022_120660 crossref_primary_10_1371_journal_pntd_0006442 crossref_primary_10_1080_19490976_2020_1859813 crossref_primary_10_1093_infdis_jiy312 crossref_primary_10_1016_j_ebiom_2021_103308 crossref_primary_10_1080_19490976_2021_1891852 crossref_primary_10_3389_fmicb_2022_983403 crossref_primary_10_1101_cshperspect_a029546 crossref_primary_10_1038_s41541_020_00228_w crossref_primary_10_3389_fpubh_2024_1332319 crossref_primary_10_3389_fmicb_2018_00440 crossref_primary_10_1080_21645515_2019_1578922 crossref_primary_10_3390_pharmaceutics14020239 crossref_primary_10_1016_j_vaccine_2019_01_003 crossref_primary_10_3389_fcimb_2021_705468 crossref_primary_10_1128_CVI_00082_16 crossref_primary_10_1371_journal_pone_0239888 crossref_primary_10_1038_s41577_021_00583_2 crossref_primary_10_1016_j_vaccine_2017_05_034 crossref_primary_10_1016_j_jim_2019_04_003 crossref_primary_10_3390_genes7120120 crossref_primary_10_1016_j_micinf_2019_02_007 crossref_primary_10_1080_21645515_2019_1575165 crossref_primary_10_1016_j_vaccine_2019_02_025 crossref_primary_10_3390_pathogens9090714 crossref_primary_10_3389_fimmu_2024_1446072 crossref_primary_10_1080_19490976_2020_1732852 |
Cites_doi | 10.1093/oxfordjournals.aje.a115579 10.1128/iai.38.1.74-79.1982 10.1159/000233587 10.1016/0022-1759(88)90086-5 10.1093/oxfordjournals.aje.a112906 10.1371/journal.pone.0126863 10.1128/CDLI.11.6.1022-1027.2004 10.1016/j.vaccine.2011.06.084 10.1016/0264-410X(91)90130-X 10.1586/erv.12.37 10.1016/j.vaccine.2011.05.021 10.1016/j.bpg.2003.11.004 10.2310/7060.2005.12207 10.1016/S0264-410X(03)00077-X 10.1128/CVI.00391-08 10.1016/j.vaccine.2006.12.028 10.1016/S0264-410X(00)00056-6 10.1016/0264-410X(95)00102-7 10.1016/0264-410X(93)90002-F 10.1128/iai.56.2.387-394.1988 10.1097/QCO.0b013e32833dfca5 10.1586/14760584.2014.905745 10.1016/S0140-6736(82)91568-9 10.1186/1471-2458-13-S3-S11 10.1128/iai.23.3.729-736.1979 10.1146/annurev.immunol.23.021704.115723 10.1128/IAI.66.7.3311-3316.1998 10.1097/00006454-200204000-00012 10.1016/j.coi.2008.03.016 10.1128/CVI.05194-11 10.1128/CMR.18.3.465-483.2005 10.1093/infdis/153.3.527 10.1128/CVI.00364-12 10.1128/IAI.01021-09 |
ContentType | Journal Article |
Copyright | Copyright © 2016, American Society for Microbiology. All Rights Reserved. Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology |
Copyright_xml | – notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved. – notice: Copyright © 2016, American Society for Microbiology. All Rights Reserved. 2016 American Society for Microbiology |
DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 7QL 7T5 C1K H94 5PM |
DOI | 10.1128/CVI.00617-15 |
DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic Bacteriology Abstracts (Microbiology B) Immunology Abstracts Environmental Sciences and Pollution Management AIDS and Cancer Research Abstracts PubMed Central (Full Participant titles) |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic AIDS and Cancer Research Abstracts Immunology Abstracts Bacteriology Abstracts (Microbiology B) Environmental Sciences and Pollution Management |
DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE AIDS and Cancer Research Abstracts |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Biology |
DocumentTitleAlternate | Immune Responses to ETEC Challenge Model in Humans |
EISSN | 1556-679X |
EndPage | 64 |
ExternalDocumentID | PMC4711095 26581889 10_1128_CVI_00617_15 |
Genre | Randomized Controlled Trial Research Support, Non-U.S. Gov't Journal Article |
GrantInformation_xml | – fundername: PATH Vaccine Solutions grantid: 103904 |
GroupedDBID | --- .GJ 0R~ 29B 2WC 39C 4.4 53G 5GY 5VS AAFWJ AAGFI AAUOK AAYXX ADBBV AENEX AGVNZ ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CITATION CS3 DIK DU5 E3Z EBS EJD F5P GX1 H13 HYE HZ~ KQ8 O9- RHI RNS RPM RSF TR2 W2D W8F WOQ CGR CUY CVF ECM EIF NPM RHF UCJ 7X8 7QL 7T5 C1K H94 5PM |
ID | FETCH-LOGICAL-c417t-aedf38c9c64b3b069ab186fff321d302c8ba33221f4c9cf495366109439e482f3 |
ISSN | 1556-6811 |
IngestDate | Thu Aug 21 14:00:53 EDT 2025 Thu Sep 04 22:34:05 EDT 2025 Fri Sep 05 06:58:07 EDT 2025 Thu Jan 02 23:10:33 EST 2025 Tue Jul 01 03:05:53 EDT 2025 Thu Apr 24 23:01:54 EDT 2025 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
License | Copyright © 2016, American Society for Microbiology. All Rights Reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c417t-aedf38c9c64b3b069ab186fff321d302c8ba33221f4c9cf495366109439e482f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 Deceased. Present address: Andrea Feller, Novartis Institutes for BioMedical Research, Cambridge, Massachusetts, USA; A. Louis Bourgeois, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA. Citation Chakraborty S, Harro C, DeNearing B, Ram M, Feller A, Cage A, Bauers N, Bourgeois AL, Walker R, Sack DA. 2016. Characterization of mucosal immune responses to enterotoxigenic Escherichia coli vaccine antigens in a human challenge model: response profiles after primary infection and homologous rechallenge with strain H10407. Clin Vaccine Immunol 23:55–64. doi:10.1128/CVI.00617-15. |
OpenAccessLink | https://cvi.asm.org/content/cdli/23/1/55.full.pdf |
PMID | 26581889 |
PQID | 1760864182 |
PQPubID | 23479 |
PageCount | 10 |
ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_4711095 proquest_miscellaneous_1762369765 proquest_miscellaneous_1760864182 pubmed_primary_26581889 crossref_primary_10_1128_CVI_00617_15 crossref_citationtrail_10_1128_CVI_00617_15 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2016-01-01 |
PublicationDateYYYYMMDD | 2016-01-01 |
PublicationDate_xml | – month: 01 year: 2016 text: 2016-01-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States – name: 1752 N St., N.W., Washington, DC |
PublicationTitle | Clinical and vaccine immunology |
PublicationTitleAlternate | Clin Vaccine Immunol |
PublicationYear | 2016 |
Publisher | American Society for Microbiology |
Publisher_xml | – name: American Society for Microbiology |
References | e_1_3_2_26_2 e_1_3_2_27_2 e_1_3_2_28_2 e_1_3_2_29_2 e_1_3_2_20_2 Raqib R (e_1_3_2_32_2) 2004; 11 e_1_3_2_21_2 e_1_3_2_22_2 Levine MM (e_1_3_2_14_2) 1982; 33 e_1_3_2_24_2 e_1_3_2_25_2 Levine MM (e_1_3_2_23_2) 1980; 111 e_1_3_2_9_2 e_1_3_2_15_2 e_1_3_2_8_2 e_1_3_2_16_2 e_1_3_2_37_2 e_1_3_2_7_2 e_1_3_2_17_2 Wennerås C (e_1_3_2_3_2) 2004; 22 e_1_3_2_6_2 e_1_3_2_18_2 e_1_3_2_19_2 e_1_3_2_30_2 e_1_3_2_10_2 e_1_3_2_31_2 e_1_3_2_5_2 e_1_3_2_11_2 e_1_3_2_34_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_33_2 e_1_3_2_13_2 e_1_3_2_36_2 e_1_3_2_2_2 e_1_3_2_35_2 Svennerholm AM (e_1_3_2_38_2) 1982 6746103 - Int Arch Allergy Appl Immunol. 1984;75(1):38-43 6120313 - Lancet. 1982 Feb 6;1(8267):305-8 26020966 - PLoS One. 2015;10(5):e0126863 3512729 - J Infect Dis. 1986 Mar;153(3):527-34 12744870 - Vaccine. 2003 Jun 2;21(19-20):2394-403 3373004 - J Immunol Methods. 1988 May 25;110(1):85-91 21852546 - Clin Vaccine Immunol. 2011 Oct;18(10):1719-27 8438608 - Vaccine. 1993;11(2):100-6 20683261 - Curr Opin Infect Dis. 2010 Oct;23(5):481-7 6127806 - Scand J Infect Dis Suppl. 1982;33:83-95 3276624 - Infect Immun. 1988 Feb;56(2):387-94 10781858 - Vaccine. 2000 Jun 1;18(24):2704-12 16020685 - Clin Microbiol Rev. 2005 Jul;18(3):465-83 2157338 - Am J Epidemiol. 1990 May;131(5):886-904 15771575 - Annu Rev Immunol. 2005;23:367-86 6754618 - Infect Immun. 1982 Oct;38(1):74-9 15123079 - Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):421-45 17224212 - Vaccine. 2007 Mar 30;25(14):2545-66 15539500 - Clin Diagn Lab Immunol. 2004 Nov;11(6):1022-7 22873126 - Expert Rev Vaccines. 2012 Jun;11(6):677-94 15996455 - J Travel Med. 2005 Mar-Apr;12(2):102-7 12075764 - Pediatr Infect Dis J. 2002 Apr;21(4):322-30 21616116 - Vaccine. 2011 Aug 11;29(35):5869-85 20086085 - Infect Immun. 2010 Apr;78(4):1750-9 23035175 - Clin Vaccine Immunol. 2012 Dec;19(12):1921-31 378834 - Infect Immun. 1979 Mar;23(3):729-36 1887674 - Vaccine. 1991 Jun;9(6):428-31 19193833 - Clin Vaccine Immunol. 2009 Apr;16(4):521-7 21723899 - Vaccine. 2011 Aug 26;29(37):6167-78 6987863 - Am J Epidemiol. 1980 Mar;111(3):347-55 8578831 - Vaccine. 1995 Nov;13(16):1488-94 24564510 - BMC Public Health. 2013;13 Suppl 3:S11 24702311 - Expert Rev Vaccines. 2014 May;13(5):631-9 18456483 - Curr Opin Immunol. 2008 Apr;20(2):162-9 15663170 - J Health Popul Nutr. 2004 Dec;22(4):370-82 9632600 - Infect Immun. 1998 Jul;66(7):3311-6 |
References_xml | – ident: e_1_3_2_12_2 doi: 10.1093/oxfordjournals.aje.a115579 – ident: e_1_3_2_16_2 doi: 10.1128/iai.38.1.74-79.1982 – ident: e_1_3_2_31_2 doi: 10.1159/000233587 – ident: e_1_3_2_37_2 doi: 10.1016/0022-1759(88)90086-5 – volume: 111 start-page: 347 year: 1980 ident: e_1_3_2_23_2 article-title: Lack of person-to-person transmission of enterotoxigenic Escherichia coli despite close contact publication-title: Am J Epidemiol doi: 10.1093/oxfordjournals.aje.a112906 – ident: e_1_3_2_36_2 doi: 10.1371/journal.pone.0126863 – volume: 11 start-page: 1022 year: 2004 ident: e_1_3_2_32_2 article-title: Use of antibodies in lymphocyte secretions for detection of subclinical tuberculosis infection in asymptomatic contacts publication-title: Clin Diagn Lab Immunol doi: 10.1128/CDLI.11.6.1022-1027.2004 – ident: e_1_3_2_4_2 doi: 10.1016/j.vaccine.2011.06.084 – ident: e_1_3_2_26_2 doi: 10.1016/0264-410X(91)90130-X – ident: e_1_3_2_9_2 doi: 10.1586/erv.12.37 – ident: e_1_3_2_22_2 doi: 10.1016/j.vaccine.2011.05.021 – ident: e_1_3_2_17_2 doi: 10.1016/j.bpg.2003.11.004 – ident: e_1_3_2_2_2 doi: 10.2310/7060.2005.12207 – ident: e_1_3_2_27_2 doi: 10.1016/S0264-410X(03)00077-X – ident: e_1_3_2_35_2 doi: 10.1128/CVI.00391-08 – volume: 33 start-page: 83 year: 1982 ident: e_1_3_2_14_2 article-title: Reactogenicity, immunogenicity and efficacy studies of Escherichia coli type 1 somatic pili parenteral vaccine in man publication-title: Scand J Infect Dis Suppl – ident: e_1_3_2_18_2 doi: 10.1016/j.vaccine.2006.12.028 – ident: e_1_3_2_21_2 doi: 10.1016/S0264-410X(00)00056-6 – ident: e_1_3_2_29_2 doi: 10.1016/0264-410X(95)00102-7 – ident: e_1_3_2_5_2 – ident: e_1_3_2_11_2 doi: 10.1016/0264-410X(93)90002-F – ident: e_1_3_2_15_2 doi: 10.1128/iai.56.2.387-394.1988 – ident: e_1_3_2_8_2 doi: 10.1097/QCO.0b013e32833dfca5 – ident: e_1_3_2_10_2 doi: 10.1586/14760584.2014.905745 – start-page: 305 year: 1982 ident: e_1_3_2_38_2 article-title: Intestinal antibody responses after immunisation with cholera B subunit publication-title: Lancet doi: 10.1016/S0140-6736(82)91568-9 – ident: e_1_3_2_6_2 doi: 10.1186/1471-2458-13-S3-S11 – ident: e_1_3_2_13_2 doi: 10.1128/iai.23.3.729-736.1979 – ident: e_1_3_2_33_2 doi: 10.1146/annurev.immunol.23.021704.115723 – ident: e_1_3_2_25_2 doi: 10.1128/IAI.66.7.3311-3316.1998 – volume: 22 start-page: 370 year: 2004 ident: e_1_3_2_3_2 article-title: Prevalence of enterotoxigenic Escherichia coli-associated diarrhoea and carrier state in the developing world publication-title: J Health Popul Nutr – ident: e_1_3_2_30_2 doi: 10.1097/00006454-200204000-00012 – ident: e_1_3_2_34_2 doi: 10.1016/j.coi.2008.03.016 – ident: e_1_3_2_20_2 doi: 10.1128/CVI.05194-11 – ident: e_1_3_2_7_2 doi: 10.1128/CMR.18.3.465-483.2005 – ident: e_1_3_2_19_2 doi: 10.1093/infdis/153.3.527 – ident: e_1_3_2_24_2 doi: 10.1128/CVI.00364-12 – ident: e_1_3_2_28_2 doi: 10.1128/IAI.01021-09 – reference: 15539500 - Clin Diagn Lab Immunol. 2004 Nov;11(6):1022-7 – reference: 24564510 - BMC Public Health. 2013;13 Suppl 3:S11 – reference: 8438608 - Vaccine. 1993;11(2):100-6 – reference: 15771575 - Annu Rev Immunol. 2005;23:367-86 – reference: 24702311 - Expert Rev Vaccines. 2014 May;13(5):631-9 – reference: 12075764 - Pediatr Infect Dis J. 2002 Apr;21(4):322-30 – reference: 12744870 - Vaccine. 2003 Jun 2;21(19-20):2394-403 – reference: 20683261 - Curr Opin Infect Dis. 2010 Oct;23(5):481-7 – reference: 378834 - Infect Immun. 1979 Mar;23(3):729-36 – reference: 15123079 - Best Pract Res Clin Gastroenterol. 2004 Apr;18(2):421-45 – reference: 6746103 - Int Arch Allergy Appl Immunol. 1984;75(1):38-43 – reference: 8578831 - Vaccine. 1995 Nov;13(16):1488-94 – reference: 17224212 - Vaccine. 2007 Mar 30;25(14):2545-66 – reference: 2157338 - Am J Epidemiol. 1990 May;131(5):886-904 – reference: 1887674 - Vaccine. 1991 Jun;9(6):428-31 – reference: 15996455 - J Travel Med. 2005 Mar-Apr;12(2):102-7 – reference: 16020685 - Clin Microbiol Rev. 2005 Jul;18(3):465-83 – reference: 15663170 - J Health Popul Nutr. 2004 Dec;22(4):370-82 – reference: 3512729 - J Infect Dis. 1986 Mar;153(3):527-34 – reference: 21616116 - Vaccine. 2011 Aug 11;29(35):5869-85 – reference: 22873126 - Expert Rev Vaccines. 2012 Jun;11(6):677-94 – reference: 19193833 - Clin Vaccine Immunol. 2009 Apr;16(4):521-7 – reference: 3373004 - J Immunol Methods. 1988 May 25;110(1):85-91 – reference: 6754618 - Infect Immun. 1982 Oct;38(1):74-9 – reference: 10781858 - Vaccine. 2000 Jun 1;18(24):2704-12 – reference: 26020966 - PLoS One. 2015;10(5):e0126863 – reference: 6120313 - Lancet. 1982 Feb 6;1(8267):305-8 – reference: 6127806 - Scand J Infect Dis Suppl. 1982;33:83-95 – reference: 18456483 - Curr Opin Immunol. 2008 Apr;20(2):162-9 – reference: 23035175 - Clin Vaccine Immunol. 2012 Dec;19(12):1921-31 – reference: 6987863 - Am J Epidemiol. 1980 Mar;111(3):347-55 – reference: 21723899 - Vaccine. 2011 Aug 26;29(37):6167-78 – reference: 9632600 - Infect Immun. 1998 Jul;66(7):3311-6 – reference: 20086085 - Infect Immun. 2010 Apr;78(4):1750-9 – reference: 21852546 - Clin Vaccine Immunol. 2011 Oct;18(10):1719-27 – reference: 3276624 - Infect Immun. 1988 Feb;56(2):387-94 |
SSID | ssj0043687 |
Score | 2.2944028 |
Snippet | Enterotoxigenic
Escherichia coli
(ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers.... Enterotoxigenic Escherichia coli (ETEC) bacteria are the most common bacterial cause of diarrhea in children in resource-poor settings as well as in travelers.... |
SourceID | pubmedcentral proquest pubmed crossref |
SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source |
StartPage | 55 |
SubjectTerms | Antibodies, Bacterial - blood Antibody Formation Antigens, Bacterial - immunology Diarrhea - immunology Diarrhea - microbiology Diarrhea - prevention & control Enterotoxigenic Escherichia coli - chemistry Enterotoxigenic Escherichia coli - immunology Enterotoxigenic Escherichia coli - pathogenicity Escherichia coli Escherichia coli Infections - immunology Escherichia coli Infections - microbiology Escherichia coli Infections - prevention & control Escherichia coli Proteins - immunology Escherichia coli Vaccines - administration & dosage Escherichia coli Vaccines - immunology Feces - microbiology Fimbriae Proteins - immunology Humans Immunity, Mucosal Immunoglobulin A - blood Saliva - immunology Spotlight Vaccines |
Title | Characterization of Mucosal Immune Responses to Enterotoxigenic Escherichia coli Vaccine Antigens in a Human Challenge Model: Response Profiles after Primary Infection and Homologous Rechallenge with Strain H10407 |
URI | https://www.ncbi.nlm.nih.gov/pubmed/26581889 https://www.proquest.com/docview/1760864182 https://www.proquest.com/docview/1762369765 https://pubmed.ncbi.nlm.nih.gov/PMC4711095 |
Volume | 23 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ta9RAEF5qRRFBtL6db4ygn47UZPO25zc5K1fhimBb-i1s3mjgTOSaE9v_6f9xZnezyV2rVL-EI7fZZDNPdmZ2n5lh7I3r57mHisGRWZw5QSwCZyJRIGj8Su4HQZlLWu-YH0Szo-DzSXiydePugLW0atPd7OLKuJL_kSqeQ7lSlOw_SNZ2iifwN8oXjyhhPF5LxlObbfnCWn5zoqBTAg0K_KCiDIoDqxM5KAZA0zY_KQVnlY33zkhkFdGdxwiIanwsM9pop5QC1ERxZaVZ6J92ZVdU_bSFZtLpzincgBI8nZmS419MCot9w_TShOdZ841mWuLcorFqe1MrwV9VqYrxDN02XZ7WZk_oIjephx_m8Soa29p-gGEnoC-huWur9HQp-9l1qaN5pgt53va8g4_FAX7npqiL2Xjp9730WrFcED1zuDbiDddGzHQeRk4kzHReDM7FqoCv1QE65nkN63pC1zmEjWmg861fVjqcAimmx_u7yiB0vLBXrh2hYEPnWiak8sG4SPDqRF2dUMaEmzyOFelArT1pu4JKBahSQd2YujAOLt4N771uYF3ymjbJvwNr6vA-u2fcIPigMf2AbRX1DrulC6Oe77Dbc0P5eMh-bYIcmhIMyEGDHCzIoW1gA-QwADkQyMGAHDqQQ1WDBAVysCAHBfL3tmvoIA4K4mAgDhbigACFHuIwgDgQxEFDHDTEH7GjT3uH05ljapE4WeDFrSOLvPRFNsmiIPVTN5rI1BNRWZY-93Lf5ZlIpY_K0SsDbFQSazuiSgZo7xeB4KX_mG3XTV08ZZCW6BV5JRdhjiakm6ZxGEs_JMIhlXfzR2zcCTDJTKJ-esJFchVYRuytbf1dD_0P7V53WEhQg9C2oKwLfB-JF0euiAJP8L-24X6Ergv280Tjx96NoxPjCTEZsXgNWbYBZbBf_6euTlUme7SM8R2Fz645hufsTv-Vv2Db7XJVvESfoE1fqU_lNy4MFL8 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Characterization+of+Mucosal+Immune+Responses+to+Enterotoxigenic+Escherichia+coli+Vaccine+Antigens+in+a+Human+Challenge+Model%3A+Response+Profiles+after+Primary+Infection+and+Homologous+Rechallenge+with+Strain+H10407&rft.jtitle=Clinical+and+vaccine+immunology&rft.au=Chakraborty%2C+Subhra&rft.au=Harro%2C+Clayton&rft.au=DeNearing%2C+Barbara&rft.au=Ram%2C+Malathi&rft.date=2016-01-01&rft.issn=1556-6811&rft.eissn=1556-679X&rft.volume=23&rft.issue=1&rft.spage=55&rft.epage=64&rft_id=info:doi/10.1128%2FCVI.00617-15&rft.externalDBID=n%2Fa&rft.externalDocID=10_1128_CVI_00617_15 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1556-6811&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1556-6811&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1556-6811&client=summon |